Profile data is unavailable for this security.
About the company
Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-88.12m
- Incorporated2011
- Employees11.00
- LocationRenovaro IncCentury City Medical Plaza2080 Century City East, Suite 906LOS ANGELES 90067United StatesUSA
- Phone+1 (212) 763-0184
- Fax+1 (845) 818-3588
- Websitehttps://renovarobio.com/
Mergers & acquisitions
Acquired company | RENB:NAQ since announced | Transaction value |
---|---|---|
Gedi Cube Bv | -87.72% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aeon Biopharma Inc | 0.00 | -305.52m | 56.91m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
Allakos Inc | 0.00 | -206.00m | 57.76m | 131.00 | -- | 0.6877 | -- | -- | -2.35 | -2.35 | 0.00 | 0.9454 | 0.00 | -- | -- | 0.00 | -86.62 | -42.71 | -99.21 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
Enzo Biochem Inc | 33.34m | -17.55m | 58.15m | 179.00 | -- | 0.8386 | -- | 1.74 | -0.3516 | 0.9194 | 0.6633 | 1.35 | 0.4028 | 1.66 | 4.91 | 186,257.00 | -21.20 | -12.21 | -34.50 | -15.79 | 43.66 | 37.09 | -52.63 | -18.76 | 3.16 | -- | 0.053 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
Omega Therapeutics Inc | 6.31m | -78.90m | 59.02m | 93.00 | -- | 2.25 | -- | 9.35 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
Mural Oncology PLC | 0.00 | -173.30m | 59.12m | 117.00 | -- | 0.2871 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
Aerovate Therapeutics Inc | 0.00 | -87.94m | 59.18m | 51.00 | -- | 0.6266 | -- | -- | -3.14 | -3.14 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -65.76 | -- | -74.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Shattuck Labs Inc | 4.12m | -85.28m | 60.14m | 75.00 | -- | 0.5437 | -- | 14.58 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
Bioqual Inc | 62.86m | 957.02k | 60.37m | 108.00 | 63.08 | 1.55 | 17.21 | 0.9604 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
Renovaro Inc | 0.00 | -88.12m | 60.85m | 11.00 | -- | 0.3609 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 61.16m | 12.00 | -- | 6.02 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
Serina Therapeutics Inc | 179.00k | -18.67m | 61.99m | 4.00 | -- | -- | -- | 346.33 | -9.72 | -9.72 | 0.0403 | -1.86 | 0.0156 | -- | 6.28 | 44,750.00 | -162.58 | -194.46 | -- | -- | 49.72 | 85.80 | -10,438.55 | -2,347.36 | -- | -1.82 | -- | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
Champions Oncology Inc | 51.66m | -3.40m | 62.40m | 210.00 | -- | -- | -- | 1.21 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
Vivani Medical Inc | 0.00 | -24.20m | 62.44m | 44.00 | -- | 2.62 | -- | -- | -0.4643 | -0.4643 | 0.00 | 0.4316 | 0.00 | -- | -- | 0.00 | -44.89 | -56.58 | -50.97 | -67.66 | -- | -- | -- | -2,868.72 | -- | -- | 0.00 | -- | -- | -- | -84.69 | -- | 40.33 | -- |
RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
OS Therapies Inc | 0.00 | -6.55m | 63.16m | 4.00 | -- | -- | -- | -- | -0.3011 | -0.3011 | 0.00 | -1.32 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.9763 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
Maia Biotechnology Inc | 0.00 | -28.08m | 63.59m | 13.00 | -- | 19.97 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.90m | 2.65% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.73m | 1.17% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 373.60k | 0.25% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 306.14k | 0.21% |
Millennium Management LLCas of 31 Mar 2024 | 293.63k | 0.20% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 257.04k | 0.17% |
Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 187.45k | 0.13% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 178.09k | 0.12% |
Jane Street Capital LLCas of 31 Mar 2024 | 133.84k | 0.09% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 120.35k | 0.08% |